# Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis

> **NCT02472938** · PHASE4 · WITHDRAWN · sponsor: **Biogen**

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** dimethyl fumarate
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02472938
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-07
- **Primary completion:** 2019-07
- **Final completion:** 2020-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2015-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02472938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02472938, "Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02472938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*